Age | 58 岁 |
patients with coronary heart disease | Yes
|
Sign the informed consent | Yes
|
Risk stratification for patients with low or middle risk | middle risk
|
Patients in one of the following condition are excluded | none
|
Name | WAWX |
gender | 男 |
people | 汉 |
Height | 174 cm |
weight | 88.3 kg |
abdomen circumference | 104 cm |
left ventricular ejection fraction(LVEF) | 59% |
stents implanted | No
|
anamnesis | hypertension
/arrhythmia
|
Body Mass Index | 29.17 kg/m2 |
smoking history | No
|
blood cholesterol level in hospital | 3.78 mmol/l |
drink history | No
|
Bad mood performance | anxiety
|
exercise habit | No
|
The drug | antiplatelet drug
/β-Receptor blockers
/statins
|
heart rate in anaerobic domain | 125 次/分 |
heart rate in the peak oxygen uptake | 125 次/分 |
blood pressure in Anaerobic domain | 136/86 mm/Hg |
blood pressure in the peak oxygen uptake | 136/86 mm/Hg |
the oxygen uptake in the rest | 0.312 ml/kg/min |
the oxygen uptake in anaerobic threshold | 1.315 ml/kg/min |
Peak oxygen uptake | 1.315 ml/kg/min |
target heart rate | 100 次/分 |
Treadmill load | 57 w |
blood pressure in the rest | 73 次/分 |
blood pressure in the rest | 119/84 mm/Hg |
Phosphodiesterase 9A | ng/ml |
Inflammatory factors | ng/ml |
Immune-modulatory marker | ng/ml |
left ventricular dysfunction marker | ng/ml |
myeloperoxidase | ng/ml |
adiponectin | ng/ml |
extracellular-matrix remodeling markers | ng/ml |
heart rate in anaerobic domain | 127 次/分 |
heart rate in the peak oxygen uptake | 125 次/分 |
blood pressure in the rest | 159/84 mm/Hg |
blood lipid level in Peak oxygen uptake period | 136/86 mm/Hg |
the oxygen uptake in the rest | 0.297 ml/kg/min |
the oxygen uptake in anaerobic threshold | 1.529 ml/kg/min |
Peak oxygen uptake | 1.841 ml/kg/min |
target heart rate | 110 次/分 |
Treadmill load | 89 w |
heart rate in the rest | 70 次/分 |
blood pressure in the rest | 117/85 mm/Hg |
Phosphodiesterase 9A | ng/ml |
Inflammatory factors | ng/ml |
Immune-modulatory marker | ng/ml |
left ventricular dysfunction marker | ng/ml |
myeloperoxidase | ng/ml |
adiponectin | ng/ml |
extracellular-matrix remodeling markers | ng/ml |
Patients with follow-up of 3 months is discomfort or not | No
|
stick to exercise or not in the follow-up after 3 months | Yes
|